News
04-02-2013, 05:30 AM
NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.
More... (http://www.news-medical.net/news/20130402/NewLink-Genetics-starts-Phase-2-clinical-study-of-indoximod-in-patients-with-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130402/NewLink-Genetics-starts-Phase-2-clinical-study-of-indoximod-in-patients-with-metastatic-breast-cancer.aspx)